• 1
    Fleisch H 2000 Bisphosphonates in Bone Disease. Academic Press, New York, NY, USA.
  • 2
    Papapoulos SE, Cremers SC 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 10751076.
  • 3
    Marini J 2004. Nelson Textbook of Pediatrics, 17th ed. Saunders, Philidelphia, PA, USA.
  • 4
    Byers PH, Cole WG 2002 Osteogenesis imperfecta. In: RoycePM, SteinmannB (eds.) Connective Tissue and Its Heritable Disorders, 2nd ed. Wiley-Liss, New York, NY, USA, 385430.
  • 5
    Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G 1997 Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131: 622625.
  • 6
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947952.
  • 7
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 18461850.
  • 8
    Giraud F, Meunier PJ 2002 Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 69: 486490.
  • 9
    Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15: 163174.
  • 10
    Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573578.
  • 11
    Zeitlin L, Rauch F, Plotkin H, Glorieux FH 2003 Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111: 10301036.
  • 12
    Arikoski P, Silverwood B, Tillmann V, Bishop NJ 2004 Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34: 539546.
  • 13
    Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L 2006 Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149: 174179.
  • 14
    Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 12931299.
  • 15
    Weber M, Roschger P, Fratzl-Zelman N, Schoberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K 2006 Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39: 616622.
  • 16
    Glorieux FH, Rauch F, Ward LM, Smith P, Verbruggen N, Heyden N, Lombardi A 2004 Alendronate in the treatment of pediatric osteogenesis imperfecta. J Bone Miner Res 19: S1 ; 1043.
  • 17
    Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C 2004 Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 363: 14271431.
  • 18
    Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S 2005 Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. J Bone Miner Res 20: 758763.
  • 19
    Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC 2005 Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20: 977986.
  • 20
    Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK Jr 2007 Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297: 480488.
  • 21
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457463.
  • 22
    Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH 2004 Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19: 17791786.
  • 23
    Chipman SD, Sweet HO, McBride DJ Jr , Davisson MT, Marks SC Jr , Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR 1993 Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: A model of human osteogenesis imperfecta. Proc Natl Acad Sci USA 90: 17011705.
  • 24
    Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC 1999 Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J Biol Chem 274: 3792337931.
  • 25
    Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L, Bergwitz C, Forlino A, Osdoby P, Gronowicz G, Marini JC 2008 Cellular mechanism of decreased bone formation in Brtl mouse: Increased ostoclasts are independent of decreased osteoblast function and RANKL/OPG ratio. J Bone Miner Res 23: 19831994.
  • 26
    Kozloff KM, Carden A, Bergwitz C, Forlino A, Uveges TE, Morris MD, Marini JC, Goldstein SA 2004 Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res 19: 614622.
  • 27
    McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP 2002 Aln treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model. Pediatr Res 52: 660670.
  • 28
    Camacho NP, Braytov CF, Buckmeyer J, Raggio CL, Root L, Toledano TR 1997 Evaluation of Aln for treatment in an animal model of osteogenesis imperfecta. J Bone Miner Res 12S: 389.
  • 29
    Kuhn JL, Goldstein SA, Choi K, London M, Feldkamp LA, Matthews LS 1989 Comparison of the trabecular and cortical tissue moduli from human iliac crests. J Orthop Res 7: 876884.
  • 30
    Hibbeler RC 1993 Statics and Mechanics of Materials. Macmillan Publishing, New York, NY, USA.
  • 31
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595610.
  • 32
    Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL 2001 A controlled study of the effects of Aln in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69: 94101.
  • 33
    Evans KD, Lau ST, Oberbauer AM, Martin RB 2003 Aln affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 32: 268274.
  • 34
    Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP 2005 Differential effects of Aln treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36: 150158.
  • 35
    Allen MR, Burr DB 2007 Three years of Aln treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22: 17591765.
  • 36
    Munns CF, Rauch F, Travers R, Glorieux FH 2005 Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res 20: 12351243.
  • 37
    Marini JC 2003 Do bisphosphonates make children's bones better or brittle ? N Engl J Med 349: 423426.
  • 38
    Camacho NP, Carroll P, Raggio CL 2003 Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int 72: 604609.
  • 39
    Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC 2003 Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33: 960969.
  • 40
    Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524531.
  • 41
    Iwata K, Li J, Follet H, Phipps RJ, Burr DB 2006 Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39: 10531058.
  • 42
    Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144: 54415449.